Eylea erodes Lucentis, Avastin market share

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

Five things for pharma marketers to know: Tuesday, August 4

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in ...

Express Scripts drops Onglyza from 2016 formulary over safety concerns

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Point of Care: Point of Where?

With rare exceptions, the point of care used to be one of three places: the doctor's office, the hospital or the pharmacy. But with advancing ...

Leadership Exchange: 21st Century Promotion

From the 21st Century Cures Act to Amarin's off-label suit, Marc Iskowitz asks seven experts what the confluence of policy developments means for pharma promotion.

Latest

Firms promising Rx savings deepen ties to EHR platforms

Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.

Healthcare reimagined: Fortner finesses McKesson's bold vision

Healthcare reimagined: Fortner finesses McKesson's bold vision

From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

MM&M Awards 2015: The Short List

MM&M Awards 2015: The Short List

More than 100 handpicked healthcare marketing professionals spent hours analyzing and debating your MM&M Awards entries. Here are the ones that made the finalist cut

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 31

Five things for pharma marketers to know: Friday, July 31

Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment

Wunderman Health acquires ABS Creative

The New York-based agency took a majority stake in the full-service healthcare agency.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

More patients are seeking treatments with even fewer side effects and shorter durations.

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Graphic: the new hepatitis-C drug market

Graphic: the new hepatitis-C drug market

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Agency Spotlight


Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.